The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships
Open accessAbstract
Objectives: To determine the existence of concentration-toxicity relationships for common β-lactam antibiotic adverse effects and define thresholds above which toxicity is more likely. Patients and methods: Retrospective review of consecutive patients treated with piperacillin, meropenem or flucloxacillin who underwent therapeutic drug monitoring (TDM) at St Vincent's Hospital (Sydney, Australia) between January 2013 and December 2015. Adverse events investigated included neurotoxicity, nephrotoxicity, hepatotoxicity and opportunistic Clostridium difficile infection. Toxicity was measured using observational grading criteria, clinical assessment and relevant serum biomarkers. These findings were correlated with trough TDM measurements at the time of toxicity presentation. Results: TDM results from 378 patients (piperacillin = 223, meropenem = 94 and flucloxacillin = 61) were investigated. There was no difference in baseline patient characteristics across antibiotic groups. A statistically significant elevation in mean serum trough concentrations (Cmin) was found in patients diagnosed with neurotoxicity (piperacillin, P < 0.01; meropenem, P = 0.04; flucloxacillin, P = 0.01) and those who developed nephrotoxicity whilst being treated with piperacillin (P < 0.01) or meropenem (P < 0.01). Incidence of hepatotoxicity and C. difficile was not related to Cmin. Threshold concentrations for which there is 50% risk of developing a neurotoxicity event (piperacillin, Cmin >361.4 mg/L; meropenem, Cmin >64.2 mg/L; flucloxacillin, Cmin >125.1 mg/L) or nephrotoxicity (piperacillin, Cmin >452.65 mg/L; meropenem, Cmin >44.45 mg/L) varied across antibiotics. Conclusions: Our data reveal an association between toxic concentrations for a number of β-lactam agents and neurotoxic/nephrotoxic effects. We have defined threshold concentrations above which these toxicities become more likely. Clinicians should balance concerns for therapeutic efficacy with potential toxicity when considering aggressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Case definition and phenotype standardization in drug-induced liver injury
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., Hunt, C. M., Wilke, R. A., Avigan, M., Kaplowitz, N., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.58 · Cited by 944
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
study, F. T. D., Daly, A. K., International SAE Consortium, Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., et al. (2009) · Nature Genetics · doi:10.1038/ng.379 · Cited by 944
Assessment and prognosis of coma after head injury
Teasdale, G., & Jennett, B. (1976) · Acta Neurochirurgica · doi:10.1007/bf01405862 · Cited by 822
Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection
Brown, K. A., Khanafer, N., Daneman, N., & Fisman, D. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02176-12 · Cited by 587
Neurotoxic effects associated with antibiotic use: management considerations
Grill, M. F., & Maganti, R. K. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03991.x · Cited by 410
Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408
Cited by
Guilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Rationalizing antimicrobial therapy in the ICU: a narrative review
Timsit, J.-F., Bassetti, M., Cremer, O., Daikos, G., de Waele, J., Kallil, A., Kipnis, E., Kollef, M., Laupland, K., Paiva, J.-A., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05520-5 · Cited by 266
Can epilepsy be treated by antibiotics?
Braakman, H. M. H., & van Ingen, J. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8943-3 · Cited by 70
Ehmann, L., Zoller, M., Minichmayr, I. K., Scharf, C., Huisinga, W., Zander, J., & Kloft, C. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.06.016 · Cited by 67
Hurkacz, M., Dobrek, L., & Wiela-Hojeńska, A. (2021) · Molecules · doi:10.3390/molecules26247456 · Cited by 60
Metadata
- Authors
- Imani, S., Buscher, H., Marriott, D., Gentili, S., & Sandaradura, I.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-07-10
- Volume
- 72
- Issue
- 10
- Pages
- 2891-2897
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2735133396
- Cited by
- 320
- References
- 33
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships. https://app.cochat.ai/papers/10.1093/jac/dkx209
- The paper
- Imani, S., Buscher, H., Marriott, D., Gentili, S., & Sandaradura, I. (2017). Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkx209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.